Literature DB >> 19581457

In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.

Sydney M Finegold1, Mauricio Bolanos, Paula H Sumannen, Denise R Molitoris.   

Abstract

The antimicrobial activities of telavancin and six comparators were evaluated against 460 isolates of anaerobic bacteria. Telavancin demonstrated excellent activity against gram-positive anaerobes (MIC90, 2 microg/ml) and was the most potent agent tested against Clostridium difficile (MIC90, 0.25 microg/ml). As expected, gram-negative isolates were not inhibited by telavancin.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19581457      PMCID： PMC2737894          DOI： 10.1128/AAC.00908-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  16S ribosomal DNA sequence-based analysis of clinically significant gram-positive anaerobic cocci.

Authors:  Yuli Song; Chengxu Liu; Maureen McTeague; Sydney M Finegold
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

2.  Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424).

Authors:  Michael R Leadbetter; Stacy M Adams; Bettina Bazzini; Paul R Fatheree; Dane E Karr; Kevin M Krause; Bernice M T Lam; Martin S Linsell; Matthew B Nodwell; John L Pace; Kelly Quast; Jeng-Pyng Shaw; Elizabeth Soriano; Sean G Trapp; Jenny D Villena; Terry X Wu; Burton G Christensen; J Kevin Judice
Journal:  J Antibiot (Tokyo)       Date:  2004-05       Impact factor: 2.649

3.  Diagnosis and treatment of diabetic foot infections.

Authors:  Benjamin A Lipsky; Anthony R Berendt; H Gunner Deery; John M Embil; Warren S Joseph; Adolf W Karchmer; Jack L LeFrock; Daniel P Lew; Jon T Mader; Carl Norden; James S Tan
Journal:  Plast Reconstr Surg       Date:  2006-06       Impact factor: 4.730

4.  In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.

Authors:  W T M Jansen; A Verel; J Verhoef; D Milatovic
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

5.  Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate.

Authors:  K I Plaisance; G L Drusano; A Forrest; R J Townsend; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

6.  Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.

Authors:  Kimberly D Leuthner; Chrissy M Cheung; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2006-06-20       Impact factor: 5.790

7.  Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.

Authors:  Martin E Stryjewski; William D O'Riordan; William K Lau; Francis D Pien; Lala M Dunbar; Marc Vallee; Vance G Fowler; Vivian H Chu; Elizabeth Spencer; Steven L Barriere; Michael M Kitt; Christopher H Cabell; G Ralph Corey
Journal:  Clin Infect Dis       Date:  2005-04-28       Impact factor: 9.079

Review 8.  Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections.

Authors:  Alasdair P MacGowan
Journal:  J Antimicrob Chemother       Date:  2003-05       Impact factor: 5.790

Review 9.  The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial infections.

Authors:  K E Aldridge
Journal:  Am J Surg       Date:  1995-05       Impact factor: 2.565

10.  Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.

Authors:  Martin E Stryjewski; Donald R Graham; Samuel E Wilson; William O'Riordan; David Young; Arnold Lentnek; Douglas P Ross; Vance G Fowler; Alan Hopkins; H David Friedland; Steven L Barriere; Michael M Kitt; G Ralph Corey
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079
View more
  4 in total

Review 1.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

Review 2.  Anaerobic infections: update on treatment considerations.

Authors:  Elisabeth Nagy
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

3.  Telavancin.

Authors:  Katherine A Lyseng-Williamson; Stephanie K A Blick
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 4.  Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.

Authors:  Adamantia Liapikou; Katerina Dimakou; Michael Toumbis
Journal:  Ther Adv Respir Dis       Date:  2016-06-23       Impact factor: 4.031
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.